News and Announcements
PMAC Trust Announce Positive Annual Results
- Published July 20, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The PMAC Trust announced a return of 18.06% this past June quarter.
- The Trust will be offering a promotion of no application fee for the next one million units issued.
PMAC Trust has announced the positive annual returns for the June quarter. The trust announced a return of 18.06%, a significant increase on previous quarters. The PMAC trust’s cash position was closer to their target of 5% this quarter and two substantial loans were advanced. The loans have drawn down principal and charges the full interest rate on the amount and not the lower line fee. Additionally, two non-performing loans have been accumulating PMA’s management fee. The Trust now has a weighted average interest rate of 14.42% per annum and a low Loan to Value Ration across all their loans.
The trust has exceeded their target return of 12 % for the past twelve months and 12.91% since the Trust inception in 2015. The past 12 months have seen the Trust assess over 259 loans resulting in 19 new loan advances. The PMAC Trust funded 18 in full or in part of the 19 loans that advanced. The PMAC will now run a special offer of a no application fee for the next one million units issued.
About Private Mortgages Australia
Direct and Pooled investment opportunities available. Directors of PMA, and their associates Co-Invest in mortgages. PMA was established in 2014. Credit Committee has over 50 years combined experience in private lending, investment & credit analysis. Proven track record of providing regular high returns. Cleaner loans, better results.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
